Introduction. Prognostic and predictive value of PD-L1 as a biomarker in breast cancer remains controversial. While some studies suggest its association with negative prognostic parameters, others reported a highly significant association between PD-L1 expression and tumor-infiltrating lymphocytes, which are known to be an independent favorable prognostic factor. The aim of present study is to examine the relationship between immune response markers and PD-L1 expression in early breast cancer. Material and methods. Immunohistochemical expression of PD-L1, along with density and composition of stromal lymphocytic infiltrate and peritumoral lymphoid aggregates was analyzed in 95 samples of invasive breast cancer. Results. A strong positive co...
The development of immune checkpoints inhibitors represents one of the major recent advances in onco...
Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer case...
The immunogenicity of breast cancer (BC) is quite heterogeneous among the clinical subtypes, with im...
Cancer immunotherapy and especially immune checkpoint blockade therapy has revolutionized cancer tre...
Programmed death 1 (PD-1) is a co-inhibitory receptor in the CD28/CTL-4 family, and functions as a n...
Abstract Background: Immune biologic markers that can predict clinical response to anti-PD-1/PD-L1 t...
Recent studies in multiple epithelial cancers have shown thatthe inhibitory receptor programmed cell...
Background The implementation of immunological biomarkers for radiotherapy (RT) individualization in...
To better understand the expression pattern of programmed death-ligand 1 (PD-L1) expression in diffe...
The clinical relevance of tumor-infiltrating lymphocytes (TIL) in breast cancer (BC) has been clearl...
PD-L1 and PD-L2 constitute an important antitumor immune response. In breast cancer, their prognosti...
Triple negative breast cancer patients have a poor course of disease not least because of limited tr...
Background: Studies pointed out that the tumor-infiltrating lymphocytes (TILs) have considerable imp...
BACKGROUND: Expression of programmed death ligand 1 (PD-L1) in solid tumours has been shown to predi...
International audienceImmune checkpoint regulators such as PD-L1 have become exciting new therapeuti...
The development of immune checkpoints inhibitors represents one of the major recent advances in onco...
Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer case...
The immunogenicity of breast cancer (BC) is quite heterogeneous among the clinical subtypes, with im...
Cancer immunotherapy and especially immune checkpoint blockade therapy has revolutionized cancer tre...
Programmed death 1 (PD-1) is a co-inhibitory receptor in the CD28/CTL-4 family, and functions as a n...
Abstract Background: Immune biologic markers that can predict clinical response to anti-PD-1/PD-L1 t...
Recent studies in multiple epithelial cancers have shown thatthe inhibitory receptor programmed cell...
Background The implementation of immunological biomarkers for radiotherapy (RT) individualization in...
To better understand the expression pattern of programmed death-ligand 1 (PD-L1) expression in diffe...
The clinical relevance of tumor-infiltrating lymphocytes (TIL) in breast cancer (BC) has been clearl...
PD-L1 and PD-L2 constitute an important antitumor immune response. In breast cancer, their prognosti...
Triple negative breast cancer patients have a poor course of disease not least because of limited tr...
Background: Studies pointed out that the tumor-infiltrating lymphocytes (TILs) have considerable imp...
BACKGROUND: Expression of programmed death ligand 1 (PD-L1) in solid tumours has been shown to predi...
International audienceImmune checkpoint regulators such as PD-L1 have become exciting new therapeuti...
The development of immune checkpoints inhibitors represents one of the major recent advances in onco...
Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer case...
The immunogenicity of breast cancer (BC) is quite heterogeneous among the clinical subtypes, with im...